- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04802447
SurVaxM Expanded Access Protocol (EAP)
November 8, 2021 updated by: Roswell Park Cancer Institute
Expanded Access to SurVaxM for Treatment of Patients With Glioblastoma Who Have No Access to Other Comparable or Alternative Therapy or Have Completed Treatment on a Non-Randomized Clinical Trial of SurVaxM and May Benefit From Further Treatment
Data from clinical trials suggest that SurVaxM administered as a single agent, or in combination with standard glioblastoma chemotherapy treatment regimens to patients with recurrent or newly diagnosed glioblastoma, is generally well tolerated and may increase progression free survival and overall survival in some patients
Study Overview
Study Type
Expanded Access
Expanded Access Type
- Treatment IND/Protocol
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
This EAP is intended for the following patients only:
- Roswell Park patients with glioblastoma who are not eligible for an appropriate clinical trial for their glioblastoma, but who meet required eligibility criteria listed herein and,
- Roswell Park patients with glioblastoma who have completed participation in a nonrandomized clinical trial of SurVaxM, but who wish to continue to receive SurVaxM as part of their ongoing care, and who meet all other eligibility criteria listed herein and,
- Patients at institutions other than Roswell Park who have completed treatment on a nonrandomizedclinical trial of SurVaxM at their participating institution, but who wish to continue to receive SurVaxM as part of their ongoing care, and who meet all other eligibility criteria listed herein. Such patients must agree to, and be able to, participate at Roswell Park.
Inclusion Criteria:
- Patient has newly diagnosed or recurrent or progressive glioblastoma who falls under one or more exclusion criteria of another SurVaxM clinical study currently recruiting, or has completed participation in another non-randomized clinical trial of SurVaxM for glioblastoma and is off study but wishes to receive SurVaxM as part of his/her treatment
- Karnofsky performance status ≥ 70 (refer to Appendix A).
- A pathologically confirmed diagnosis of glioblastoma of the brain or spinal cord is required, unless biopsy is determined by the PI not to be in the patient's best interest.
- Have the following clinical laboratory values obtained within 28 days prior to registration:
- Absolute neutrophil count (ANC) ≥ 1.0 x 109/L
- Creatinine ≤ 1.8 mg/dL
- Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin or oral anticoagulants) must meet the following criteria:
- No active bleeding or pathological condition that carries a high risk of bleeding (e.g., coagulopathy)
- For participants of child-bearing potential: must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to enrollment and, have a negative pregnancy test prior to starting treatment under this protocol.
- Dose of corticosteroids reduced to the minimum required to control neurologic symptoms.
- Patients with newly diagnosed glioblastoma must have completed radiation therapy and temozolomide or "standard of care" treatment of their glioblastoma, unless it is determined by their treating physician that it is not in the best interest of the patient to do so.
- Participant must understand the investigational nature of this study drug and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving SurVaxM.
- Patient is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other procedures.
Exclusion Criteria:
- Patient meets all inclusion criteria for another SurVaxM clinical study that is open and recruiting.
- Patient has previously participated in a clinical trial in which randomization to an arm with SurVaxM treatment was part of the trial design..
- Patients with newly diagnosed or recurrent glioblastoma who have not had standard of care treatment with fractionated radiation therapy and temozolomide, unless these treatments have been determined to be medically contraindicated or are not tolerate.
- Patient's brain tumor has not been biopsied, unless biopsy is determined by the PI not to be in the patient's best interest.
- Patient has serious concurrent infection or medical illness, which in the treating physician's opinion would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety.
- History of tuberculosis, granulomatous disease or systemic autoimmune disorder.
- Patient is pregnant or breast-feeding.
- Concurrent participation in any clinical therapeutic studies involving investigational drug(s) (Phases 1-4).
- Patient has concurrent or prior malignancy except curatively treated carcinoma-in-situ or basal cell carcinoma of the skin. Patients who have been free of disease (any prior malignancy) for at least 2 years may be eligible for treatment under this protocol.
- Patient who is receiving any other concurrent chemotherapeutic agents or investigational drugs.
- Known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS) related illness or other serious medical illness.
- Patient is unwilling or unable to follow protocol requirements.
- Any condition which in the Investigator's opinion makes the candidate unsuitable to receive the study drug or protocol procedures.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ajay Abad, MD, Roswell Park Cancer Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
March 8, 2021
First Submitted That Met QC Criteria
March 16, 2021
First Posted (Actual)
March 17, 2021
Study Record Updates
Last Update Posted (Actual)
November 16, 2021
Last Update Submitted That Met QC Criteria
November 8, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- I 546319
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on SurVaxM
-
MimiVax, LLCTranslational Drug Development; MeritActive, not recruitingNewly Diagnosed GlioblastomaUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI); Roswell Park Cancer Institute; American Lebanese...RecruitingGlioblastoma Multiforme | Ependymoma | Medulloblastoma | Anaplastic Astrocytoma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Diffuse Intrinsic Pontine Glioma | High-grade Astrocytoma NOSUnited States, Canada
-
Hui-Sheng ChenRecruitingStroke, Ischemic | Mechanical Thrombectomy | Intravascular ThrombosisChina
-
Center for Clinical Pharmacology Research Bdbeq...Laboratorio Elea Phoenix S.A.Unknown
-
David PeereboomActive, not recruitingRecurrent GlioblastomaUnited States
-
Center for Clinical Pharmacology Research Bdbeq...Laboratorio Elea Phoenix S.A.UnknownBioequivalencyUruguay
-
Roswell Park Cancer InstituteNot yet recruitingMalignant Solid Neoplasm | Lung Neuroendocrine Neoplasm | Digestive System Neuroendocrine Neoplasm | Pancreatic Neuroendocrine NeoplasmUnited States